CSIMarket
 
Celularity Inc   (CELU)
Other Ticker:  
 
 
Price: $5.6000 $-0.08 -1.408%
Day's High: $5.86 Week Perf: -5 %
Day's Low: $ 5.60 30 Day Perf: 36.92 %
Volume (M): 45 52 Wk High: $ 8.90
Volume (M$): $ 250 52 Wk Avg: $4.10
Open: $5.86 52 Wk Low: $1.59



 Market Capitalization (Millions $) 1,055
 Shares Outstanding (Millions) 188
 Employees 201
 Revenues (TTM) (Millions $) 15
 Net Income (TTM) (Millions $) -181
 Cash Flow (TTM) (Millions $) -37
 Capital Exp. (TTM) (Millions $) 6

Celularity Inc
Celularity Inc. is a biotechnology company based in Warren, New Jersey, United States. It was founded in 2017 by Dr. Robert Hariri and Peter Diamandis with a mission to revolutionize the field of regenerative medicine through the development of innovative cellular therapies. The company focuses on harnessing the power of placental cells to create transformative treatments for a variety of diseases, including cancer, infectious diseases, and autoimmune disorders.

The uniqueness of Celularity comes from its proprietary platform technology, which utilizes placental cells obtained from full-term deliveries. These cells possess a remarkable ability to regenerate tissues and modulate immune responses, making them ideal candidates for therapeutic applications. Celularityes platform technology involves the isolation and characterization of placental cells, including placental hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), which can then be expanded in culture to generate large quantities of cells for therapeutic use.

Celularityes pipeline includes several cellular therapies that are currently in clinical trials or preclinical development. One of its most promising candidates is Cynk-001, an off-the-shelf, allogeneic natural killer (NK) cell therapy derived from placental HSCs. NK cells are a type of immune cell that can directly kill cancer cells and virally-infected cells without prior sensitization, making them ideal for cancer immunotherapy. Cynk-001 has shown great promise in clinical trials for various types of cancer, including multiple myeloma, acute myeloid leukemia, and ovarian cancer.

In addition to cellular therapies, Celularityes platform technology has potential applications in other areas. The company has developed a placental-derived extracellular matrix (ECM) product called Axiologik, which has demonstrated the ability to promote tissue repair and regeneration. Axiologik is being evaluated as a potential treatment for chronic wounds, burns, and other tissue injuries.

Celularity Inc. is a privately-held company that has received significant investment from notable biotech investors, including United Therapeutics Corporation, Sorrento Therapeutics, and Dreyfus Health Foundation. The company has also formed strategic partnerships with other industry leaders, such as United Parcel Service (UPS), for the development of logistics and supply chain solutions for the delivery of cellular therapies.

Overall, Celularity Inc. is a cutting-edge biotech company that is at the forefront of the regenerative medicine field. Its innovative use of placental cells and platform technology has the potential to transform the treatment of a variety of diseases and improve patient outcomes.


   Company Address: 170 Park Ave Florham Park 7932 NJ
   Company Phone Number: 768-2170   Stock Exchange / Ticker: NASDAQ CELU
   CELU is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Revolutionary Allogeneic Cell Therapy Derived from the Placenta Shows Promise in Reducing Cancer Tumors: Groundbreaking Study Presented at AACR Annual Meeting 2024

Published Thu, Mar 7 2024 2:35 PM UTC

Celularity, a leading clinical-stage cell therapeutics company, is set to present groundbreaking data at the AACR Annual Meeting in 2024. The data showcases the potential of PT-CD16, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells, in reducing cancer tumors. This exciting development in the field of cell therapy brings ho...

Shares

Celularity Implements Reverse Stock Split to Boost Market Position and Meet Nasdaq Requirements

Published Fri, Feb 23 2024 9:10 PM UTC

Celularity, a biotechnology company specializing in allogeneic cell therapies and advanced biomaterial products, recently announced a significant development that is set to impact its stock value. The company's Board of Directors has approved a 1-for-10 reverse stock split of its Class A common stock, effective February 28, 2024, in an effort to meet the minimum bid price re...

Product Service News

Celularity Forecasts Stellar Growth in 2024: A Deep Dive into Advanced Biomaterial Product Business and Biobanking

Published Thu, Feb 1 2024 2:01 PM UTC

In line with an impressive growth trajectory initiated in 2023, Celularity Inc. recently unveiled its net sales projections for the first quarter and the entire year of 2024. Notably, the company is expecting a triple-digit percentage surge in the combined net sales of its cutting-edge biomaterial product business and biobanking operations. This calculated anticipation is bu...

Financing Agreement

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions, Demonstrating Commitment to Advancing Cellular Therapies.

Published Thu, Jan 25 2024 2:00 PM UTC

Celularity Secures $21 Million in Financing as the Major Pharmaceutical Preparations Industry Experiences Growth
Celularity, a leading biotechnology company focused on developing innovative cellular therapies, recently announced the successful closure of two financing transactions, highlighting the company's resilience and commitment to its growth strategy. As of January...

Stock Market Announcement

Celularity Releases CEO Letter to Shareholders: A Promising Outlook for Future Growth

Published Thu, Jan 18 2024 6:41 PM UTC



Celularity Inc. recently posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, outlining the company's progress and future plans. This article will delve into the highlights from the letter and provide insights into Celularity's recent performance and its potential for growth. As of the writing of this article, Celularity I...






 

Celularity Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com